AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
AdaptHealth Corp. is the issuer in an amended beneficial-ownership report by Reinhart Partners, LLC, which reports beneficial ownership of 0 shares of common stock, or 0% of the class. Reinhart Partners reported zero sole or shared voting power and zero sole or shared dispositive power.
AdaptHealth Corp. is the issuer of common shares for which Dimensional Fund Advisors reported beneficial ownership of 6,394,796 shares, or 4.7%, as of September 30, 2026. Dimensional reported sole voting power over 6,261,514 shares and sole dispositive power over 6,394,796 shares, with no shared voting or dispositive power. It stated that the securities are owned by the Funds it advises and disclaimed beneficial ownership.
AdaptHealth Corp. (symbol: AHCO) is the issuer of record for a Form 4 filing submitted to the SEC. CURRIE HARRISS T reported acquisition or exercise transactions in this Form 4 filing.
AdaptHealth Corp. (AHCO) reported that its Chief Financial Officer, Harriss T. Currie, received a grant of 141,372 shares of Common Stock in the form of restricted stock units on September 9, 2026. These restricted stock units will be settled in common stock upon vesting, and Currie now directly holds 141,372 shares. No Rule 10b5-1 trading plan is reported for this transaction.
AdaptHealth Corp. (AHCO) filed an initial statement of beneficial ownership for its Chief Financial Officer, Currie Harriss T. The filing reports that the CFO currently holds no shares of AdaptHealth common stock as of the reporting date. The filing also references an Exhibit 24 Power of Attorney.
AdaptHealth Corp. (AHCO) announced a planned Chief Financial Officer transition, appointing Harriss Currie as CFO effective September 9, 2026, while current CFO Jason Clemens will cease serving as CFO on September 8, 2026 and remain through October 1, 2026 to assist with the transition.
Currie joins with extensive healthcare and diagnostics experience, including more than 15 years as CFO of Luminex Corp. His employment agreement provides an annual base salary of $670,000 and a target annual bonus equal to 100% of base salary, with a prorated 2026 bonus. As an inducement, he will receive RSUs valued at $818,462, half vesting annually over three years and half cliff-vesting on the third anniversary of his start date, subject to continued employment. Upon certain qualifying terminations, he is eligible for 12 months of base-salary severance, a prorated bonus (under stated conditions), and 12 months of COBRA health coverage, subject to a release and restrictive covenants.
AdaptHealth Corp. director Dale B. Wolf reported an amended Form 4 reflecting the correct pricing for a recent share purchase. On 2026-08-06, he purchased 20,000 shares of common stock in open-market or private transactions at an average price of $6.30 per share, with individual trade prices ranging from $6.26 to $6.335. Following these transactions, he directly holds 143,234 shares of AdaptHealth common stock and indirectly holds 34,000 shares through the Dale B. Wolf Generation Skipping Trust, for which he serves as investment manager.
AdaptHealth Corp. director Kenneth A. Samet purchased additional common stock in an open-market or private transaction. On 2026-08-06 he bought 23,500 shares at $6.38 per share, bringing his directly held position to 48,569 shares of AdaptHealth common stock.
AdaptHealth Corp. director Dale B. Wolf reported open-market purchases of common stock on two consecutive days. On August 6, 2026, he purchased 20,000 shares at $6.37 per share, bringing his directly held position to 143,234 shares. On August 7, 2026, an additional 20,000 shares were purchased at a weighted average price of $5.86 per share, in multiple trades between $5.83 and $5.885, for the Dale B. Wolf Generation Skipping Trust, which now holds 34,000 shares with Wolf as investment manager.
AdaptHealth Corp. reported results for the quarter ended June 30, 2026. Net revenue from continuing operations was $740,307 (in thousands) compared with $657,100 (in thousands) a year earlier. The company recorded a net loss attributable to AdaptHealth of $133,929 (in thousands) versus net income of $14,674 (in thousands), driven largely by a non-cash goodwill impairment of $144,236 (in thousands) in the Respiratory Health and Wellness at Home reporting units.
Net income from discontinued operations related to the Diabetes Health business was $11,387 (in thousands) in the quarter. In June 2026 the board approved divestiture of this business, and on July 19, 2026 AdaptHealth agreed to sell it for $235.0 million in cash, with closing expected in the first quarter of 2027 subject to regulatory review and customary conditions. For the six months, net cash provided by operating activities was $239,024 (in thousands), while long-term debt (less current portion) was $1,879,809 (in thousands) following an April 2026 refinancing that established a new term loan and revolving credit facility.
AdaptHealth reported second-quarter 2026 net revenue of $740.3 million, up 12.7% from $657.1 million, with 15.9% organic growth across all segments. A $144.2 million goodwill impairment in the Respiratory Health and Wellness at Home reporting units drove a sharp swing to a net loss attributable to AdaptHealth Corp. of $145.3 million versus net income of $4.2 million a year earlier. Adjusted EBITDA slipped 3.2% to $132.0 million, with margin declining to 17.8% from 20.8%. Year-to-date 2026 cash from operations was $239.0 million versus $257.5 million, and free cash flow turned negative $48.4 million versus $73.3 million in 2025. Registered myAPP users surpassed 512,000, 56% above year-end 2025.
The company agreed to sell its Diabetes Health business for $235.0 million in cash, which will be reported as discontinued operations, and formed an e-commerce joint venture adding home sleep testing. Management completed a workforce restructuring expected to yield $19 million in annualized savings and refinanced, redeeming 6.125% Senior Notes due 2028 using a $325 million delayed-draw term loan. Full-year 2026 guidance on a continuing-operations basis was reset to net revenue of $2.85–$2.89 billion, Adjusted EBITDA of $490–$520 million, and free cash flow of $80–$120 million. Versus prior EBITDA guidance of $680–$730 million, the revision reflects a $100 million impact from classifying Diabetes Health as discontinued operations (including $60 million of overhead that will partly remain), plus $55 million from the West Coast capitated contract, $30 million from a manufacturer price increase, and $15 million from other portfolio actions.